IL1B and atherosclerosis: The CANTOS phase III randomized clinical trial was designed to evaluate the role of IL-1β inhibition in preventing the recurrence of cardiovascular events in patients with atherosclerosis (21); unexpectedly, treatment with the anti–IL-1β mAb canakinumab resulted in a dose-dependent reduction in lung cancer incidence and mortality.